Maroun Aoun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maroun Aoun has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Fong H. Nham
Department of Orthopedic Surgery and Sports Medicine, Detroit Medical Center, Detroit, MI, USA
3 shared publications - Mohammad Daher
Division of Spine Surgery, Department of Orthopaedic Surgery, Duke University School of Medicine, Durham, North Carolina, USA
3 shared publications - Mouhanad M. El-Othmani
Warren Alpert Medical School, Brown University, Providence, RI 02903, USA
3 shared publications - Farid Mallat
Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
2 shared publications Md
2 shared publications- Bassel Elzorkany
Cairo University, Cairo, Egypt
1 shared publication
Latest Publications
- 26 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Global patterns and determinants of diagnostic delay in spondyloarthritis: insights from the ASAS-PerSpA international study
Objectives: Diagnostic delay (DD) is well-documented in SpA, particularly in axial disease. This ancillary analysis from the ASAS-PerSpA study estimated DD across SpA entities, considering the presenting disease manifestation, and evaluated factors associated with DD. Methods: This study included 4339 patients with any SpA entity (axial (axSpA), peripheral (pSpA), PsA, inflammatory bowel disease-associated SpA (IBD-SpA), ReA and juvenile SpA). DD was assessed using two definitions: (1) the first included extra-musculoskeletal manifestation (EMM) if any, as possible initial symptom, and (2) the second considered strictly the first musculoskeletal manifestation (MM) as the disease onset. DD was statistically compared across disease entities, and associated factors were evaluated using multivariable linear regression models for axSpA, PsA, pSpA and IBD-SpA. Results: The analysis included 2622 axSpA, 1016 PsA, 424 pSpA, 110 IBD-SpA, and 167 other SpA patients. The average DD was shorter using definition 2 (4.5 ± 7.0 vs 6.6 ± 8.6 years). Based on definition 2, DD was longer for axSpA and IBD-SpA (5.6 ± 7.3 and 5.2 ± 7.7 years, respectively), where the first MM was axial, compared with PsA (2.5 ± 6.1 years), pSpA (3.1 ± 5.9 years) and others, where it was peripheral (P < 0.001). Axial first manifestation, younger age at first symptom and older age at study inclusion were associated with longer DD in the four SpA entities. Conclusion: DD was longer in axSpA and IBD-SpA compared with PsA, pSpA and other forms of SpA and associated with the phenotype of the presenting symptom. SpA entities and presenting symptoms should be considered when reporting DD in SpA.
- 26 September 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (1)
Global patterns and determinants of diagnostic delay in spondyloarthritis: insights from the ASAS-PerSpA international study
Objectives: Diagnostic delay (DD) is well-documented in SpA, particularly in axial disease. This ancillary analysis from the ASAS-PerSpA study estimated DD across SpA entities, considering the presenting disease manifestation, and evaluated factors associated with DD. Methods: This study included 4339 patients with any SpA entity (axial (axSpA), peripheral (pSpA), PsA, inflammatory bowel disease-associated SpA (IBD-SpA), ReA and juvenile SpA). DD was assessed using two definitions: (1) the first included extra-musculoskeletal manifestation (EMM) if any, as possible initial symptom, and (2) the second considered strictly the first musculoskeletal manifestation (MM) as the disease onset. DD was statistically compared across disease entities, and associated factors were evaluated using multivariable linear regression models for axSpA, PsA, pSpA and IBD-SpA. Results: The analysis included 2622 axSpA, 1016 PsA, 424 pSpA, 110 IBD-SpA, and 167 other SpA patients. The average DD was shorter using definition 2 (4.5 ± 7.0 vs 6.6 ± 8.6 years). Based on definition 2, DD was longer for axSpA and IBD-SpA (5.6 ± 7.3 and 5.2 ± 7.7 years, respectively), where the first MM was axial, compared with PsA (2.5 ± 6.1 years), pSpA (3.1 ± 5.9 years) and others, where it was peripheral (P < 0.001). Axial first manifestation, younger age at first symptom and older age at study inclusion were associated with longer DD in the four SpA entities. Conclusion: DD was longer in axSpA and IBD-SpA compared with PsA, pSpA and other forms of SpA and associated with the phenotype of the presenting symptom. SpA entities and presenting symptoms should be considered when reporting DD in SpA.
- Open Access
- 1 March 2025
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 37 (1) , 45-52
Bibliometric Analysis of Dual Mobility Total Hip Arthroplasty
Marc Boutros, MD, Maroun Aoun, MD, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, MD, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:45-52. https://doi.org/10.5371/hp.2025.37.1.45
- 1 March 2025
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 37 (1) , 45-52
Open AccessBibliometric Analysis of Dual Mobility Total Hip Arthroplasty
Marc Boutros, MD, Maroun Aoun, MD, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, MD, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:45-52. https://doi.org/10.5371/hp.2025.37.1.45
- Open Access
- 1 March 2025
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 37 (1) , 53-63
Trends and Insights in Direct Anterior Total Hip Arthroplasty: A Comprehensive Bibliometric Analysis
Ralph Chalhoub, MD, Maroun Aoun, BS, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, BS, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:53-63. https://doi.org/10.5371/hp.2025.37.1.53
- 1 March 2025
- Published by The Korean Hip Society in Hip & Pelvis
- Vol. 37 (1) , 53-63
Open AccessTrends and Insights in Direct Anterior Total Hip Arthroplasty: A Comprehensive Bibliometric Analysis
Ralph Chalhoub, MD, Maroun Aoun, BS, Fong H. Nham, MD, Eliana Kassis, MD, Mohammad Daher, BS, Mouhanad M. El-Othmani, MD. Hip Pelvis 2025;37:53-63. https://doi.org/10.5371/hp.2025.37.1.53
- Open Access
- 14 January 2025
- Published by MDPI AG in Preprints.org
Effective Intramuscular Vitamin D2 in Patients with Systemic Sclerosis Non-Responding to Oral Supplementation; A Retrospective Observational Case Series
Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.
- 14 January 2025
- Published by MDPI AG in Preprints.org
Open AccessEffective Intramuscular Vitamin D2 in Patients with Systemic Sclerosis Non-Responding to Oral Supplementation; A Retrospective Observational Case Series
Objective: To assess the response to intramuscular vitamin D in patients not respond-ing to oral supplementation. Methods: A retrospective series included patients, with systemic sclerosis and a history of subclinical poor vitamin D status that was resistant to at least 6 months of oral supplementation, to whom intramuscular vitamin D2 was administered. Results: Twelve patients were identified, with a mean age of 47.8 years. All were women. Five had diffuse systemic sclerosis and seven had localized systemic sclerosis. The mean duration of the disease was 17.9 years, with a mean modified Rod-nan skin score of 14.9. All patients were twice injected, at a 15-day interval, 300,000 IU of ergocalciferol into the anterior gluteus muscle. The mean serum level of 25(OH)D increased from 12.9 ng/mL before the first injection, to 23 ng/mL two weeks after the first injection, and 37.1 ng/mL four weeks after the second injection (p<0.001). No side effects were observed. Conclusion: It is the first report of safely normalizing vitamin D levels with intramuscular ergocalciferol in patients with systemic sclerosis.
- Open Access
- 1 January 2024
- Published by XMLink in Clinics in Orthopedic Surgery
- Vol. 16 (6) , 880-889
Evolution and Hotspots in Bilateral Total Joint Arthroplasty Research: A Bibliometric Analysis
Aoun M, et al. Clin Orthop Surg. 2024 Dec;16(6):880-889. https://doi.org/10.4055/cios24114
- 1 January 2024
- Published by XMLink in Clinics in Orthopedic Surgery
- Vol. 16 (6) , 880-889
Open AccessEvolution and Hotspots in Bilateral Total Joint Arthroplasty Research: A Bibliometric Analysis
Aoun M, et al. Clin Orthop Surg. 2024 Dec;16(6):880-889. https://doi.org/10.4055/cios24114
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 2853007
Insights Into the Emerging Entity of HER2‐Low Breast Cancer
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 2853007
Open AccessInsights Into the Emerging Entity of HER2‐Low Breast Cancer
Human epidermal growth factor receptor 2 (HER2)‐low breast cancer (BC) is a subtype of BC that has been recently recognized as a separate clinical entity with distinct clinical and molecular characteristics. It is defined by a low level of HER2 protein expression, which distinguishes it from other more aggressive BC subtypes. Early studies suggest that it may have a more favorable prognosis than HER2‐positive BC, as it is less likely to spread to other parts of the body and may be more responsive to standard BC treatments such as chemotherapy, radiation therapy, and hormone therapy. Given the relative new emergence of HER2‐low BC, there is still much to be learned about this subtype; ongoing research is focused on identifying the underlying genetic mutations that contribute to HER2‐low BC as well as developing targeted therapies that can improve outcomes for patients with this disease. This review is aimed at summarizing the current clinical knowledge on HER2‐low BC, with the aim of creating a better understanding of this entity and paving the way for potential interventions and a new standard of care.
- 1 August 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (13) , 725-730
Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey
Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management...
- 1 August 2023
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 24 (13) , 725-730
Improving the Management of ALK-Rearranged Non-Small-Cell Lung Cancer Through a Mobile Application: A Physicians-Based Survey
Background: ALK rearrangements account for around 5% of non-small-cell lung cancers. Aim: This study surveys physicians on the potential efficacy of a mobile application in improving the management...